MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In

Partners will start an all-new BiTE project and continue working on another, while Micromet takes over worldwide development of blinatumomab, for which MedImmune retains a commercialization option.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet